Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia

被引：5

作者：

Kawabe, Kentaro ^{[1
]}

Horiuchi, Fumie ^{[1
,3
]}

Matsumoto, Yu ^{[2
]}

Inoue, Saori ^{[2
]}

Okazawa, Maya ^{[2
]}

Hosokawa, Rie ^{[2
]}

Nakachi, Kiwamu ^{[2
]}

Soga, Junya ^{[2
]}

Ueno, Shu-Ichi ^{[2
]}

机构：

[1] Ehime Univ, Dept Child Psychiat, Grad Sch Med, Toon City, Japan

[2] Ehime Univ, Dept Neuropsychiat Mol & Funct, Grad Sch Med, Toon City, Japan

[3] Ehime Univ, Dept Child Psychiat, Grad Sch Med, Shitsukawa 454, Toon City, Ehime 7910295, Japan

来源：

NEUROPSYCHOPHARMACOLOGY REPORTS | 2024年 / 44卷 / 01期

关键词：

ADHD; guanfacine; guideline; lisdexamfetamine; methylphenidates;

D O I：

10.1002/npr2.12381

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Attention-deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)-approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first-line treatment, with pharmacological treatment added as the second-line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines. Stimulant and nonstimulant medications have been approved for the treatment of ADHD. In 2022, new Japanese guidelines for ADHD were issued. However, the guidelines for ADHD medications across Asian regions are unclear. Therefore, we investigated Asian regional guidelines for ADHD medication.image

引用

页码：29 / 33

页数：5

共 26 条

[1]

Academy of Medicine Malaysia, 2020, MAN ATT DEF HYP DIS

[2]

[Anonymous], Children and Adults with Attention Deficit/Hyperactivity Disorder

[3] Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups [J].